Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Iowa City, Iowa.
Cancer Res Commun. 2023 Aug 17;3(8):1580-1593. doi: 10.1158/2767-9764.CRC-23-0268. eCollection 2023 Aug.
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the synthesis of deoxyribonucleosides and is required for DNA replication. Multiple types of cancer, including Ewing sarcoma tumors, are sensitive to RNR inhibitors or a reduction in the levels of either the RRM1 or RRM2 subunits of RNR. However, the polypharmacology and off-target effects of RNR inhibitors have complicated the identification of the mechanisms that regulate sensitivity and resistance to this class of drugs. Consequently, we used a conditional knockout (CRISPR/Cas9) and rescue approach to target RRM1 in Ewing sarcoma cells and identified that loss of the RRM1 protein results in the upregulation of the expression of multiple members of the activator protein-1 (AP-1) transcription factor complex, including c-Jun and c-Fos, and downregulation of c-Myc. Notably, overexpression of c-Jun and c-Fos in Ewing sarcoma cells is sufficient to inhibit cell growth and downregulate the expression of the c-Myc oncogene. We also identified that the upregulation of AP-1 is mediated, in part, by SLFN11, which is a replication stress response protein that is expressed at high levels in Ewing sarcoma. In addition, small-molecule inhibitors of RNR, including gemcitabine, and histone deacetylase inhibitors, which reduce the level of the RRM1 protein, also activate AP-1 signaling and downregulate the level of c-Myc in Ewing sarcoma. Overall, these results provide novel insight into the critical pathways activated by loss of RNR activity and the mechanisms of action of inhibitors of RNR.
RNR is the rate-limiting enzyme in the synthesis of deoxyribonucleotides. Although RNR is the target of multiple chemotherapy drugs, polypharmacology and off-target effects have complicated the identification of the precise mechanism of action of these drugs. In this work, using a knockout-rescue approach, we identified that inhibition of RNR upregulates AP-1 signaling and downregulates the level of c-Myc in Ewing sarcoma tumors.
核酶(RNR)催化脱氧核苷酸合成的限速步骤,是 DNA 复制所必需的。包括尤因肉瘤肿瘤在内的多种类型的癌症对 RNR 抑制剂或 RNR 的 RRM1 或 RRM2 亚单位水平的降低敏感。然而,RNR 抑制剂的多药理学和脱靶效应使鉴定调节对这类药物敏感性和耐药性的机制变得复杂。因此,我们使用条件性敲除(CRISPR/Cas9)和挽救方法靶向尤因肉瘤细胞中的 RRM1,并鉴定出 RRM1 蛋白的缺失导致激活蛋白-1(AP-1)转录因子复合物的多个成员的表达上调,包括 c-Jun 和 c-Fos,并下调 c-Myc。值得注意的是,c-Jun 和 c-Fos 在尤因肉瘤细胞中的过表达足以抑制细胞生长并下调 c-Myc 癌基因的表达。我们还鉴定出,AP-1 的上调部分是由 SLFN11 介导的,SLFN11 是一种复制应激反应蛋白,在尤因肉瘤中高表达。此外,RNR 的小分子抑制剂,包括吉西他滨和组蛋白去乙酰化酶抑制剂,降低 RRM1 蛋白的水平,也激活 AP-1 信号并下调尤因肉瘤中 c-Myc 的水平。总的来说,这些结果为 RNR 活性丧失激活的关键途径以及 RNR 抑制剂的作用机制提供了新的见解。
核酶(RNR)是脱氧核苷酸合成的限速酶。尽管 RNR 是多种化疗药物的靶标,但多药理学和脱靶效应使鉴定这些药物的确切作用机制变得复杂。在这项工作中,我们使用敲除-挽救方法鉴定出,抑制 RNR 会上调尤因肉瘤肿瘤中的 AP-1 信号并下调 c-Myc 的水平。